Endothelial Cell Dysregulation in Neovascular AMD

新生血管性 AMD 中的内皮细胞失调

• 批准号: 8731241
• 负责人: Mark E Kleinman
• 金额: $ 32.13万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8731241
• 关键词: Ablation; Accounting; Advisory Committees; Affect; Age related macular degeneration; Aging; American; Animal Model; Architecture; Area; Automobile Driving; Award; Basic Science; Biological; Biological Markers; Biology; Biomedical Research; Blindness; Blood; Blood Vessels; Bone Marrow Transplantation; Cell Line; Cells; Chairperson; Choroidal Neovascularization; Chromatin Remodeling Factor; Clinical; Clinical Research; Complement Activation; Coupled; Data; Detection; Development; Diagnosis; Diagnostic; Disease; Disease Progression; Drusen; Dyes; Early Diagnosis; Early Intervention; Early treatment; Endothelial Cells; Engineering; Environment; Experimental Designs; Exudative age-related macular degeneration; Eye; Faculty; Fellowship; Fluorescein Angiography; Funding; Future; Gene Expression Profile; Genetic; Goals; Grant; Growth; Human; Hypersensitivity; Image; Imaging Techniques; Immune; Immune system; Immunoglobulin Fragments; Immunologic Receptors; In Vitro; Inflammation; Interleukins; Invaded; Investigation; Journals; K-Series Research Career Programs; Kentucky; Knowledge; Laboratories; Lead; Legal; Legal Blindness; Lesion; Leukocytes; Ligands; Malignant Neoplasms; Maps; Mediating; Medicine; Mentors; Methods; Molecular; Molecular Profiling; Molecular Target; Mus; Nature; Nonexudative age-related macular degeneration; Ophthalmic examination and evaluation; Ophthalmology; Outcome; Oxidative Stress; Pathogenesis; Pathologic Processes; Pathway interactions; Patient Care; Patients; Pattern; Physicians; Positioning Attribute; Prevalence; Principal Investigator; Process; Progressive Disease; Quality of life; Regulation; Relative (related person); Reporting; Research; Research Personnel; Research Project Grants; Research Training; Retina; Retinal Diseases; Risk Factors; Role; Running; Safety; Scientist; Sensitivity and Specificity; Signal Pathway; Signal Transduction; Signaling Molecule; Specialist; Specimen; Staging; Structure of retinal pigment epithelium; Sum; Surface; Symptoms; Techniques; Testing; Therapeutic; Therapeutic Uses; Time; Tissues; Toxicology; Training; Training Programs; Transgenic Mice; Treatment Efficacy; Treatment Failure; United States; Universities; Uveal Melanoma; Vascular Diseases; Vascular Endothelial Growth Factor A; Vision; Visual; Work; allergic response; base; career; career development; cell type; chemokine; chemokine receptor; cost; cytokine; cytotoxicity; design; disorder of macula of retina; experience; imaging probe; immune activation; improved; in vivo; insight; molecular marker; mouse model; nanocrystal; neutralizing antibody; next generation; normal aging; ocular angiogenesis; pre-clinical; prevent; professor; programs; research study; response; skills; small molecule; therapeutic development; therapeutic target; vision science

DESCRIPTION (provided by applicant): The candidate is applying for a Mentored Clinical Scientist Research Career Development Award (K08) to support a 5 year research career training program that will significantly bolster his transition to faculty independence as a fellowship trained clinician-scientist specializing in vitreoretinal and macular diseases. The rigorous training program has been designed with extensive input and unyielding support from the candidate's mentor, co-mentor, chairman, and advisory committee. All training will take place in the excellent scientific and academic environment of the University of Kentucky, Department of Ophthalmology and Visual Sciences which includes an ocular angiogenesis research consortium consisting of four independent investigators. The applicant will spend the first 3 years of the program as a Research Assistant Professor and Clinical Fellow. The specific design of the fellowship is precisely detailed in the Career Development section and accompanied by a very strong institutional commitment that allows the candidate at least 80% effort performing research and 20% performing clinical duties. After completion of the fellowship, the candidate will transition to a full-time faculty position as Assistant Professor at University of Kentucky with the same institutional commitment of 80% research and 20% clinical effort. The long-term goal of the award is to offer the candidate the critical career development support to establish a pathway to faculty independence that will extensively train him as a biomedical researcher, confident and masterful specialist in the diagnosis and treatment of vitreoretinal and macular diseases, and leading academician. The candidate aims to have an independent laboratory up and running within the initial 12-18 months of the award period in order to gain early independence with his research project and develop critical principal investigator skills with guidance from his established mentors and advisory committee. The research plan has been devised by the candidate and his mentors and aims to extend his scientific expertise beyond basic vascular biology with a rich experience to develop new techniques and to utilize such methods in experimental designs to obtain critical data that expand his current fund of knowledge in order to yield fundamental insights on endothelial cell dysregulation, immuno-modulation in vascular growth, and therapeutic targets in neovascular age-related macular degeneration (AMD). AMD is a devastating blinding disease that affects as many as 10 million Americans, a number that rivals the prevalence of all cancers combined and is unfortunately expected to double by 2020. The overwhelming cause of severe vision loss in AMD is choroidal neovascularization (CNV), the growth of abnormal blood vessels beneath the retina. Despite the use of recently approved molecular therapeutics targeting vascular endothelial growth factor (VEGF)-A, the majority of patients do not regain functional vision, and a significant fraction progress to legal blindness. This treatment failure is attributed to the frequent clinical situation in which patients present to eye physicians after vision is already lost and irreversible structural and functional tissue damage has already occurred. Moreover, while patients with AMD often undergo at least one or more dilated eye examinations per year, the physician is often not able to detect CNV before it grows beneath the retina and wreaks havoc. Fortunately, there is an exciting development that may provide the first available technique for detecting incipient CNV in patients with AMD thereby allowing for earlier detection and treatment to prevent loss of vision and quality of life. This discovery was recently reported in the journal Nature and described as the first molecular marker that is specific for human CNV (Takeda et al. Nature 2009). It is an immune receptor called chemokine receptor 3 (CCR3) that is involved in allergic response and recruitment of white blood cells but may also be found on inflamed and growing blood vessels. The identification of CCR3 as a molecular signature has opened a gateway to a new understanding in vascular disease in AMD. CCR3 expression is found on the surface of the specialized endothelial cells that line the abnormal blood vessels. In this proposal, rigorous basic science investigations of the cellular circuitry that mediates this pathogenic switch will be explored in conjunction with the biological relationships between endothelial cell dysregulation, aging, immune activation, and oxidative stress. The initial aim of the study is to decipher how these established AMD risk factors regulate the progression of disease through chemokine and other immune signaling pathways in order to develop appropriately targeted diagnostics and therapeutics that will enable clinicians to offer improved care of patients suffering from AMD. A second aim focuses specifically on CCR3 biology with scientific exploration of its pathogenetic induction, expression patterns and signaling effects during endothelial cell dysregulation in neovascular AMD. In a final aim, optimized fluorescent CCR3- targeting probes will be engineered and applied to pre-clinical animal models of CNV and human cellular toxicology studies in order to obtain necessary data to proceed with future clinical studies. These specific experimental aims will provide fundamental insights into the modulatory function of the immune system, chemokine signaling, and the role of CCR3 as a molecular switch during the endothelial cell dysregulation that heralds vision loss in neovascular AMD.

描述（由申请人提供）：候选人正在申请指导临床科学家研究职业发展奖（K 08），以支持为期5年的研究职业培训计划，这将大大加强他作为一个奖学金培训的临床科学家，专门从事玻璃体视网膜和黄斑疾病的教师独立性的过渡。严格的培训计划是在候选人的导师、共同导师、主席和咨询委员会的广泛投入和坚定支持下设计的。所有培训都将在肯塔基州大学眼科和视觉科学系优越的科学和学术环境中进行，其中包括由四名独立研究人员组成的眼部血管生成研究联盟。申请人将花费该计划的前3年作为研究助理教授和临床研究员。奖学金的具体设计在职业发展部分中有详细说明，并伴随着一个非常强大的机构承诺，允许候选人至少80%的努力进行研究和20%的临床职责。完成奖学金后，候选人将过渡到全职教师职位，担任肯塔基州大学的助理教授，并承担80%的研究和20%的临床工作。该奖项的长期目标是为候选人提供关键的职业发展支持，以建立一条通往教师独立性的途径，将他广泛培养为生物医学研究人员，玻璃体视网膜和黄斑疾病诊断和治疗方面的自信和熟练的专家，以及领先的院士。候选人的目标是在奖励期的最初12-18个月内建立和运行一个独立的实验室，以便在他的研究项目中获得早期独立性，并在他的导师和咨询委员会的指导下发展关键的首席研究员技能。该研究计划由候选人及其导师设计，旨在将其科学专业知识扩展到基础血管生物学之外，并具有丰富的经验来开发新技术，并在实验设计中利用这些方法来获得关键数据，以扩展其现有的知识基金，从而对内皮细胞失调，血管生长中的免疫调节，和治疗靶点在新生血管性年龄相关性黄斑变性（AMD）。 AMD是一种毁灭性的致盲性疾病，影响多达1000万美国人，这一数字与所有癌症的患病率相媲美，不幸的是，预计到2020年将翻一番。AMD严重视力丧失的主要原因是脉络膜新生血管（CNV），即视网膜下异常血管的生长。尽管使用最近批准的靶向血管内皮生长因子（VEGF）-A的分子治疗剂，但大多数患者不能恢复功能性视力，并且显著部分进展为法律的盲。这种治疗失败归因于患者在视力已经丧失并且已经发生不可逆的结构和功能性组织损伤之后出现眼科医生的频繁临床情况。此外，虽然AMD患者通常每年至少接受一次或多次散瞳眼科检查，但医生通常无法在CNV在视网膜下生长并造成严重破坏之前检测到CNV。幸运的是，有一个令人兴奋的发展，可能提供第一个可用的技术，用于检测早期CNV的AMD患者，从而允许早期检测和治疗，以防止视力和生活质量的损失。这一发现最近在《自然》杂志上报道，并被描述为对人类CNV具有特异性的第一个分子标记（Takeda等人，Nature 2009）。它是一种称为趋化因子受体3（CCR 3）的免疫受体，参与过敏反应和白色血细胞的募集，但也可能在发炎和生长的血管中发现。 CCR 3作为分子标记的鉴定为AMD血管疾病的新认识打开了大门。CCR 3表达在排列在异常血管的特化内皮细胞的表面上。在这项提议中，将结合内皮细胞失调、衰老、免疫激活和氧化应激之间的生物学关系，探索介导这种致病开关的细胞回路的严格基础科学研究。该研究的最初目的是破译这些已确定的AMD风险因素如何通过趋化因子和其他免疫信号通路调节疾病的进展，以开发适当的靶向诊断和治疗方法，使临床医生能够为患有AMD的患者提供更好的护理。第二个目标特别关注CCR 3生物学，并对其在新生血管性AMD中内皮细胞失调期间的致病诱导、表达模式和信号传导作用进行科学探索。在最终目标中，优化的荧光CCR 3靶向探针将被工程化并应用于CNV的临床前动物模型和人类细胞毒理学研究，以获得进行未来临床研究所需的数据。这些特定的实验目的将提供基本的见解，免疫系统的调节功能，趋化因子信号，和CCR 3作为分子开关的作用，在内皮细胞失调，预示着视力丧失的新生血管性AMD。